Taysha Gene Therapies (TSHA) Price & Analysis

Compare

1,092 Followers

TSHA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.05 - $3.40

Previous CloseN/A

Volume273.02K

Average Volume (3M)3.30M

Market Cap

$823.84M

Enterprise Value$435.32M

Total Cash (Recent Filing)$312.76M

Total Debt (Recent Filing)$16.81M

Price to Earnings (P/E)―

Beta2.50

Next Earnings

Nov 12, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding272,794,900

10 Day Avg. Volume4,224,228

30 Day Avg. Volume3,295,198

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.53

Enterprise Value/Revenue53.76

Enterprise Value/Gross Profit55.66

Enterprise Value/Ebitda-4.75

Forecast

1Y Price Target

$8.75

Price Target Upside208.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressTSHA's pivotal REVEAL Part B study remains on track with site activations already in progress and patient enrollment expected to commence.

Financial StabilityThe company expects current cash will be sufficient into 2028.

Market ConfidenceThere is an increase in the price target to $14, reflecting positive sentiment in the company's future performance.

Bears Say

Long-term Efficacy And SafetyThere are several risks to the Buy thesis, including long-term efficacy and safety needing validation, public skepticism about gene therapy, and potential competition from other companies.

Taysha Gene Therapies News

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

Taysha Gene Therapies (TSHA) announced that, on September 2, 2025, the Compensation Committee of Taysha’s Board of Directors...

13d ago

TSHA

Taysha Gene Therapies’ Earnings Call: Progress Amid Challenges

Taysha Gene Therapies, Inc. (($TSHA)) has held its Q2 earnings call. Read on for the main highlights of...

17d ago

TSHA

Positive Outlook for Taysha Gene Therapies: Buy Rating Reinforced by Strong Financial Position and Promising Clinical Progress

Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, boosting the price target...

1M ago

TSHA

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord

Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $14 from $11 and keeps a...

1M ago

TSHA

Taysha Gene Therapies Advances Rett Syndrome Trials

Taysha Gene Therapies, Inc. ( ($TSHA) ) has released its Q2 earnings. Here is a breakdown of the...

1M ago

TSHA

Taysha Gene Therapies price target raised to $10 from $9 at Chardan

Chardan raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $9 and keeps a...

1M ago

TSHA

Taysha Gene Therapies: Positive Outlook with Pivotal Study and Strong Financial Health Justifies Buy Rating

In a report released today, Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies, with...

1M ago

TSHA

Taysha Gene Therapies reports Q2 EPS (9c), consensus (8c)

Reports Q2 revenue $1.986M, consensus $1.6M. “We have made strong progress across the Company supporting the advancement of...

1M ago

TSHA

TSHA Earnings this Week: How Will it Perform?

Taysha Gene Therapies, Inc. (TSHA) is scheduled to report 2nd quarter earnings on 08/12/2025, before the market opens....

1M ago

TSHA

Vinay Prasad returns to FDA as head of CBER

Vinay Prasad is returning to the Food and Drug Administration to lead the Center for Biologics Evaluation and...

1M ago

CAPR

MGTX

Taysha Gene Therapies initiated with a Buy at BofA

BofA analyst Tazeen Ahmad initiated coverage of Taysha Gene Therapies (TSHA) with a Buy rating and $8 price...

2M ago

ACAD

TSHA

Taysha Gene Therapies initiated with a Buy at BofA

BofA initiated coverage of Taysha Gene Therapies (TSHA) with a Buy rating and $8 price target Published first...

2M ago

TSHA

Buy Rating for Taysha Gene Therapies: Favorable Study Design and High Responder Rate

Analyst Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) and...

3M ago

TSHA

Craig-Hallum bullish on Neurogene, initiates with a Buy

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50...

3M ago

NGNE

TSHA

TSHA FAQ

What was Taysha Gene Therapies’s price range in the past 12 months?

Taysha Gene Therapies lowest stock price was $1.05 and its highest was $3.40 in the past 12 months.

What is Taysha Gene Therapies’s market cap?

Taysha Gene Therapies’s market cap is $823.84M.

When is Taysha Gene Therapies’s upcoming earnings report date?

Taysha Gene Therapies’s upcoming earnings report date is Nov 12, 2025 which is in 55 days.

How were Taysha Gene Therapies’s earnings last quarter?

Taysha Gene Therapies released its earnings results on Aug 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.012.

Is Taysha Gene Therapies overvalued?

According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Taysha Gene Therapies pay dividends?

Taysha Gene Therapies does not currently pay dividends.

What is Taysha Gene Therapies’s EPS estimate?

Taysha Gene Therapies’s EPS estimate is -0.09.

How many shares outstanding does Taysha Gene Therapies have?

Taysha Gene Therapies has 272,794,900 shares outstanding.

What happened to Taysha Gene Therapies’s price movement after its last earnings report?

Taysha Gene Therapies reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went up 5.435%.

Which hedge fund is a major shareholder of Taysha Gene Therapies?

Currently, no hedge funds are holding shares in TSHA

Taysha Gene Therapies Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.86%

Trailing 12-Months

Asset Growth

66.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Taysha Gene Therapies

Taysha Gene Therapies (TSHA) is a biotechnology company focused on developing innovative gene therapies for patients with monogenic diseases, primarily targeting neurological disorders. The company leverages its expertise in adeno-associated virus (AAV) technology to create therapies that aim to address the underlying genetic causes of diseases such as spinal muscular atrophy (SMA) and other rare genetic disorders. Taysha operates in the gene therapy sector, striving to improve the quality of life for patients through advanced therapeutic solutions.

Taysha Gene Therapies (TSHA) Earnings & Revenues

Historic Earnings Reports

TSHA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call indicates strong progress in clinical trials, financial stability, and regulatory alignment, suggesting a positive trajectory for Taysha Gene Therapy. However, increased expenses and net loss present financial challenges.View all TSHA earnings summaries

TSHA Stock 12 Month Forecast

Average Price Target

$8.75

▲(208.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.6984615384615385,4.556923076923077,5.415384615384616,6.273846153846154,7.132307692307692,7.990769230769231,8.849230769230768,9.707692307692309,10.566153846153846,11.424615384615384,12.283076923076923,13.141538461538461,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.2946153846153843,3.749230769230769,4.203846153846154,4.658461538461538,5.113076923076923,5.567692307692308,6.022307692307693,6.476923076923077,6.931538461538461,7.386153846153846,7.840769230769231,8.295384615384616,{"y":8.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.083076923076923,3.3261538461538462,3.569230769230769,3.812307692307692,4.055384615384615,4.298461538461538,4.541538461538462,4.7846153846153845,5.027692307692307,5.270769230769231,5.513846153846154,5.756923076923076,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >